We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 21, 2022

Addition of PCSK9 Inhibitors and Ezetimibe to Statin Therapy for Cardiovascular Risk Reduction

BMJ : British Medical Journal


Additional Info

BMJ : British Medical Journal
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis
BMJ 2022 May 04;377(xx)e069116, SU Khan, SH Yedlapati, AN Lone, Q Hao, G Guyatt, N Delvaux, GET Bekkering, PO Vandvik, IB Riaz, S Li, B Aertgeerts, N Rodondi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading